Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Preetesh Jain

Showing results (141-150 of 176) with videos related to

Pageof 18
Sort By:
Molecular Cancer|September 26, 2022
TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphomaVivian Changying Jiang, Dapeng Hao, Preetesh Jain, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 11, 2021
EZH2 expression is associated with inferior overall survival in mantle cell lymphomaDiana Martinez-Baquero, Ali Sakhdari, Huan Mo, et al.
Haematologica|July 20, 2023
Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factorsSteven Le Gouill, Monika Długosz-Danecka, Simon Rule, et al.
The Lancet. Haematology|January 17, 2017
Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trialPreetesh Jain, Michael Keating, Sarah Renner, et al.
Vaccines|September 28, 2024
Humoral Immunity and Antibody Responses against Diphtheria, Tetanus, and Pneumococcus after Immune Effector Cell Therapies: A Prospective StudyGeorgios Angelidakis, Roy F Chemaly, Pranoti V Sahasrabhojane, et al.
British Journal of Haematology|November 23, 2017
The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximabPreetesh Jain, Graciela M Nogueras González, Rashmi Kanagal-Shamanna, et al.
Nature Communications|July 2, 2026
BRG1-mediated suppression of ferroptosis underlies BTK inhibitor resistanceSoo-Yeon Hwang, Xiangao Huang, Helgi Nikolli, et al.
British Journal of Haematology|September 4, 2018
Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinibPreetesh Jain, Rashmi Kanagal-Shamanna, Shaojun Zhang, et al.
Advances in Radiation Oncology|November 11, 2024
Ultra-Low-Dose Radiation for Extranodal Marginal Zone Lymphoma of the LungSusan Y Wu, Penny Q Fang, Ahmed Fetooh, et al.
Leukemia & Lymphoma|January 22, 2025
Phase 2 trial of ibrutinib in previously untreated high-risk smoldering mantle cell lymphomaCharles Gaulin, Preetesh Jain, Ranjit Nair, et al.
Pageof 18

Showing results (141-150 of 176) with videos related to

Sort By:
Pageof 18
Molecular Cancer|September 26, 2022
TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphomaVivian Changying Jiang, Dapeng Hao, Preetesh Jain, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 11, 2021
EZH2 expression is associated with inferior overall survival in mantle cell lymphomaDiana Martinez-Baquero, Ali Sakhdari, Huan Mo, et al.
Haematologica|July 20, 2023
Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factorsSteven Le Gouill, Monika Długosz-Danecka, Simon Rule, et al.
The Lancet. Haematology|January 17, 2017
Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trialPreetesh Jain, Michael Keating, Sarah Renner, et al.
Vaccines|September 28, 2024
Humoral Immunity and Antibody Responses against Diphtheria, Tetanus, and Pneumococcus after Immune Effector Cell Therapies: A Prospective StudyGeorgios Angelidakis, Roy F Chemaly, Pranoti V Sahasrabhojane, et al.
British Journal of Haematology|November 23, 2017
The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximabPreetesh Jain, Graciela M Nogueras González, Rashmi Kanagal-Shamanna, et al.
Nature Communications|July 2, 2026
BRG1-mediated suppression of ferroptosis underlies BTK inhibitor resistanceSoo-Yeon Hwang, Xiangao Huang, Helgi Nikolli, et al.
British Journal of Haematology|September 4, 2018
Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinibPreetesh Jain, Rashmi Kanagal-Shamanna, Shaojun Zhang, et al.
Advances in Radiation Oncology|November 11, 2024
Ultra-Low-Dose Radiation for Extranodal Marginal Zone Lymphoma of the LungSusan Y Wu, Penny Q Fang, Ahmed Fetooh, et al.
Leukemia & Lymphoma|January 22, 2025
Phase 2 trial of ibrutinib in previously untreated high-risk smoldering mantle cell lymphomaCharles Gaulin, Preetesh Jain, Ranjit Nair, et al.
Pageof 18